| Age |
72.9±7.8 |
| Male gender |
32 (76%) |
|
Body mass index (Kg/m
2
)
|
23.3±9.8 |
| Systolic blood pressure (mmHg) |
131±13 |
| Diastolic blood pressure (mmHg) |
76±12 |
| Aneurysm maximum diameter (mm) |
56.4±2.3 |
| Hypertension |
40 (95) |
| Diabetes mellitus or impaired glucose tolerance |
19 (45) |
| Dyslipidemia |
33 (79) |
| Chronic obstructive pulmonary disease |
4 (10) |
| Smoking |
31 (74) |
| Coronary artery disease |
11 (26) |
| Cerebrovascular disease |
11 (26) |
| Sample location |
|
| Thoracic aorta |
17 (40) |
| Abdominal aorta |
25 (60) |
| Complete blood count and blood chemistry |
|
| White blood cell (/µL) |
6376±1466 |
| Hemoglobin(g/dL) |
13.1±1.6 |
| Hematocrit (%) |
39.7±4.8 |
|
Platelet (×10
4
/µL)
|
18.1±5.3 |
| Total Cholesterol (mg/dL) |
179.1±33.4 |
| High density lipoprotein cholesterol (mg/dL) |
44.9±10.2 |
| Low density lipoprotein cholesterol (mg/dL) |
111.5±31.4 |
| Triglyceride (mg/dL) |
122.3±64.3 |
| Fasting blood glucose (mg/dL) |
85.9±0.6 |
| Fasting insulin (µU/mL) |
9.0±10.0 |
|
HemoglobinA
1C
(%)
|
5.8±0.6 |
| Homeostasis model assessment insulin resistance |
2.07±2.87 |
| Creatinine (mg/dL) |
1.03±0.3 |
| C-reactive protein (mg/dL) |
0.20±0.24 |
| Medication |
|
| Angiotensin-converting enzyme inhibitors |
5 (12) |
| Angiotensin receptor blockers |
23 (55) |
| β-blocker |
12 (29) |
| Calcium channel blockers |
31 (74) |
| Aspirin |
11 (26) |
| Statins |
25 (60) |
| Anti-diabetics |
4 (10) |
